Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-38.63%
operating margin TTM
-31.85%
revenue TTM
1.21 Billion
revenue per share TTM
22.49$
valuation ratios | |
|---|---|
| pe ratio | -21.05 |
| peg ratio | -0.27 |
| price to book ratio | 29.31 |
| price to sales ratio | 16.26 |
| enterprise value multiple | -53.35 |
| price fair value | 29.31 |
profitability ratios | |
|---|---|
| gross profit margin | 93.62% |
| operating profit margin | -31.85% |
| pretax profit margin | -37.87% |
| net profit margin | -38.63% |
| return on assets | -24.53% |
| return on equity | -84.68% |
| return on capital employed | -25.74% |
liquidity ratios | |
|---|---|
| current ratio | 3.13 |
| quick ratio | 3.08 |
| cash ratio | 2.39 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 96.76 |
| operating cycle | 153.68 |
| days of payables outstanding | 476.35 |
| cash conversion cycle | -322.67 |
| receivables turnover | 6.41 |
| payables turnover | 0.77 |
| inventory turnover | 3.77 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.52 |
| debt equity ratio | 2.92 |
| long term debt to capitalization | 0.74 |
| total debt to capitalization | 0.75 |
| interest coverage | -5.25 |
| cash flow to debt ratio | -0.44 |
cash flow ratios | |
|---|---|
| free cash flow per share | -16.67 |
| cash per share | 36.28 |
| operating cash flow per share | -16.20 |
| free cash flow operating cash flow ratio | 1.03 |
| cash flow coverage ratios | -0.44 |
| short term coverage ratios | -34.67 |
| capital expenditure coverage ratio | -33.99 |
Frequently Asked Questions
When was the last time Calliditas Therapeutics AB (publ) (NASDAQ:CALT) reported earnings?
Calliditas Therapeutics AB (publ) (CALT) published its most recent earnings results on 13-08-2024.
What is Calliditas Therapeutics AB (publ)'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Calliditas Therapeutics AB (publ) (NASDAQ:CALT)'s trailing twelve months ROE is -84.68%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Calliditas Therapeutics AB (publ) (CALT) currently has a ROA of -24.53%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did CALT's net profit margin stand at?
CALT reported a profit margin of -38.63% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is CALT's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 3.13 in the most recent quarter. The quick ratio stood at 3.08, with a Debt/Eq ratio of 2.92.